NCT05318040 - Safety, Tolerability and Pharmacokinetics of CMS121, a Drug Candidate for Alzheimer's Disease, in Healthy Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 1, 2022

Primary Completion Date

December 17, 2022

Study Completion Date

December 17, 2022

Conditions

Alzheimer Disease

Interventions

DRUG

CMS121

CMS121 is a small molecule to be delivered orally in capsule form and is a therapeutic drug candidate for treatment of Alzheimer's Disease

DRUG

Placebo

Placebo will be provided as visually matching placebo capsules.

Trial Locations (1)

Celerion, Lincoln